Clinical Trial Results

Related by string. * clinicals . CLINICAL . Clinicals . clinical : Phase III clinical trials . Phase III clinical . placebo controlled clinical trials . Phase 2b clinical / trialed . trialing . trials : Week Premium Trial . Phase III trials . randomized controlled trial / resulted . results . result : EXECUTED THE RESULTS MAY . First Quarter Results . RECORD SIMULATED RESULTS DO * *

Related by context. All words. (Click for frequent words.) 86 Preclinical Data 85 Meets Primary Endpoint 85 Drug Candidate 85 Phase 2b Clinical Trial 85 Phase III Trial 84 Phase III Clinical Trial 84 Completes Patient Enrollment 84 Completes Enrollment 83 Study Evaluating 83 Phase IIb Trial 83 Oral Fingolimod 83 Presents Preclinical Data 83 Investigational Compound 83 Phase 2a Trial 82 Phase 2b Trial 82 Patient Enrollment 82 Presents Positive 82 Anti Tumor Activity 82 Improves Survival 82 Phase 2a Clinical Trial 82 Phase IIb Clinical Trial 81 Present Preclinical Data 81 Pivotal Study 81 Combination REOLYSIN R 81 Antitumor Activity 81 Phase 2b Study 81 Survival Benefit 81 II Clinical Trial 81 Receives Orphan Drug Designation 81 Pivotal Phase III 81 Pooled Analysis 81 Well Tolerated 80 Initiates Clinical Trial 80 Previously Treated 80 Metastatic Melanoma 80 Prolongs Survival 80 Novel Oral 80 Pivotal Trial 80 Initiates Clinical 80 Patients Treated With 80 Randomized Phase 79 Novel Antibiotic 79 Preclinical Study 79 Files IND 79 Study Showed 79 Clinical Outcome 79 Combination Treatment 79 Demonstrates Positive 79 Initiate Phase 79 Advanced Melanoma 79 Patients Treated 79 Hsp# Inhibitor 79 Successfully Completes Phase 79 Shows Promising 79 Clinical Trial Evaluating 79 Statistically Significant 79 Anticancer Activity 79 Dose Ranging Study 79 Pivotal Phase 79 Initiates Phase II 79 Anti Tumor 79 Lupus Drug 79 Migraine Drug 79 JAK Inhibitor 79 IND Application 79 Nicotine Vaccine 79 Shows Efficacy 79 Low Dose 78 Lung Cancer Trial 78 FDA Accepts 78 Phase III Trials 78 Renal Cell Carcinoma 78 HCV Protease Inhibitor 78 Adjuvant Treatment 78 Long Term Efficacy 78 Trial Evaluating 78 Clinical Efficacy 78 Demonstrates Significant 78 Announces Poster Presentations 78 Initiates Enrollment 78 Single Dose 78 Clinical Trial Data 78 Gout Drug 78 NDA Submission 78 Monotherapy 78 Chronic Hepatitis C 78 FDA Approvals 78 Demonstrates Potent 78 Investigational Agent 78 Drug Fails 78 Severe Sepsis 78 Investigational Drug 78 Controlled Study 78 Initiates Phase III 78 Drug Shows Promise 78 Submits NDA 77 Improved Survival 77 Improves Outcomes 77 Hormone Refractory Prostate Cancer 77 Transdermal Patch 77 Randomized Study 77 Randomized Clinical Trial 77 RNAi Therapeutic 77 Postmenopausal Women 77 Phase IIa Clinical Trial 77 Pivotal Clinical Trial 77 Osteoporosis Drug 77 Overactive Bladder 77 Inflammatory Arthritis 77 Initiates Clinical Trials 77 Pharmacokinetic Study 77 Topline Results 77 Collaborators Present 77 Controlled Trial 77 Sangamo BioSciences Announces 77 Relapsing Multiple Sclerosis 77 IND Filing 77 Randomized Double Blind 77 Rheumatoid Arthritis Patients 77 Meta Analysis 77 Investigational Treatment 77 Epilepsy Drug 77 First Patient Enrolled 77 Protease Inhibitor 77 FDA Clears 77 Chronic Hepatitis B 77 Kinase Inhibitor 77 Granted Orphan Drug 77 Patent Covering 77 Infected Patients 77 Data Suggest 77 Heart Failure Patients 77 Lung Cancer Drug 77 Arthritis Drug 77 Receives Orphan Drug 77 Fungal Infections 77 Treatment Naïve 77 FDA Okays 77 Prospective Randomized 77 Phase III Clinical Trials 77 Double Blind Placebo 77 Pulmonary Arterial Hypertension 76 Phase 1b Clinical Trial 76 Myelodysplastic Syndromes 76 Study Demonstrates 76 Elderly Patients 76 Tezampanel 76 RNAi Therapeutics 76 Commences Phase 76 Spectrum Pharmaceuticals Announces 76 Late Breaker 76 Metastatic Colorectal Cancer 76 Adjuvant Therapy 76 Disease Modifying 76 Hepatocellular Carcinoma 76 Therapeutic Potential 76 Relapsed Multiple Myeloma 76 Improve Survival 76 Effectively Treats 76 Subgroup Analysis 76 Statin Therapy 76 Vaccine Adjuvant 76 Cholesterol Lowering Drug 76 Anticancer Drug 76 Clinical Evaluation 76 Pharmacyclics Announces 76 Begins Dosing 76 Emerging Therapies 76 Receives Milestone Payment 76 Presents Preclinical 76 Initiates Phase 76 Tyrosine Kinase Inhibitor 76 Beneficial Effects 76 Mouse Model 76 Initiate Phase III 76 Brentuximab Vedotin SGN 76 Rheumatoid Arthritis Drug 76 Demonstrates Efficacy 76 Milestone Payment 76 Receives FDA Clearance 76 Achieves Primary Endpoint 76 Hypertensive Patients 76 Vitro Activity 76 Placebo Controlled Trial 76 Unfractionated Heparin 76 Castration Resistant Prostate Cancer 76 Oral Presentations 76 Diabetic Nephropathy 76 Adjuvant Chemotherapy 76 Dose Escalation 76 Significantly Improved 76 Significantly Reduces 76 Safinamide 76 Significantly Improves 76 Prostate Cancer Vaccine 76 Combination Therapy 76 Breast Cancer Recurrence 76 JAK2 Inhibitor 76 Orally Active 76 Patients Receiving 75 Randomized Double blind 75 Drug Eluting 75 Potent Antiviral Activity 75 Patients Enrolled 75 Disease Progression 75 Pivotal Trials 75 Novel Inhibitor 75 Randomized Phase II 75 Treating Chronic 75 Novel Mechanism 75 Immunomedics Announces 75 Initiate Clinical Trial 75 First Patient Dosed 75 Treatment Regimen 75 Kidney Transplant Patients 75 Slow Progression 75 Multiple Myeloma Patients 75 Advanced Colorectal Cancer 75 Demonstrated Significant 75 Patients Undergoing 75 Treated Patients 75 Oral Calcitonin 75 Appears Safe 75 Receives Approvable Letter 75 Knee Osteoarthritis 75 Adjunctive Therapy 75 Platelet Inhibition 75 Lupus Nephritis 75 Efficacy Trial 75 Announces FDA Clearance 75 HER2 Positive Breast Cancer 75 Patients Suffering 75 HDAC Inhibitor 75 Complicated Skin 75 Myeloma Patients 75 Demonstrates Potential 75 Newly Diagnosed Multiple Myeloma 75 Confirmatory Phase 75 Pediatric Patients 75 Colorectal Cancer Patients 75 Hematological Cancers 75 Randomized Double Blind Placebo 75 Phase 2a Study 75 Neoadjuvant Chemotherapy 75 Osteoporosis Drugs 75 Monoclonal Antibody 75 Treatment Reduces 75 Relapsed Refractory 75 Advanced Renal Cell 75 Metastatic Renal Cell Carcinoma 75 Shows Promise Against 75 Proves Effective 75 Tumor Growth 75 Tolerability 75 Placebo Controlled Study 75 Clinical Study 75 Receptor Agonist 74 Hematological Malignancies 74 Randomized Trials 74 Sapacitabine 74 Phase Ib Clinical Trial 74 Metastatic Prostate Cancer 74 Small Molecule 74 Treatment Resistant 74 Renal Cancer 74 Develop Novel 74 Plaque Psoriasis 74 Completes Patient Enrolment 74 Benign Prostatic Hyperplasia 74 Mylan Receives Approval 74 Prostate Cancer Patients 74 Osteoporosis Treatment 74 Previously Untreated 74 Chronic Myeloid Leukemia 74 Brain Metastases 74 Preclinical Models 74 Recombinant Human 74 Chronic Lymphocytic Leukemia 74 Antiviral Activity 74 Randomized Controlled Trials 74 Inflammatory Markers 74 Systemic Delivery 74 Schizophrenia Drug 74 Randomized Clinical Trials 74 Reports Preclinical Data 74 Immune Responses 74 Nymox NX 74 Dendritic Cells 74 Autologous Stem Cell Transplantation 74 Therapy Improves 74 Predict Risk 74 Therapeutic Antibody 74 Cites Positive 74 Rotavirus Vaccine 74 Synthetic Peptide 74 Poster Presentations 74 Bone Metastases 74 Generic Version 74 Novel Compound 74 Preclinical Efficacy 74 Hypercholesterolemia 74 Treatment Experienced 74 Resistant Hypertension 74 Prophylactic Treatment 74 Cholesterol Drug 74 Cutaneous T 74 Glufosfamide 74 Targeted Therapies 74 Relapsing Remitting Multiple Sclerosis 74 Elagolix 74 Expanded Indication 74 Plus Ribavirin 74 Interferon Beta 74 Completes Dosing 74 Dose Response 74 Gets FDA Clearance 74 Desvenlafaxine Succinate 74 Newly Diagnosed 74 Combination Clinical Trial 74 Lung Cancer Patients 74 Significantly Reduced 74 Hemodialysis Patients 74 First Patient Treated 74 Stent Implantation 74 Collaborators Publish 74 Advanced Prostate Cancer 74 Oral Formulation 73 Is Well Tolerated 73 Announces Initiation 73 Gene Mutation 73 Hormone Receptor Positive 73 Breast Cancer Cells 73 Proven Effective 73 Lowers Risk 73 Therapeutic Competitors Companies 73 Versus Placebo 73 Non Invasive 73 Files Investigational 73 Earns Milestone Payment 73 Commence Phase 73 Cancer Treatments 73 Placebo Controlled 73 Vicriviroc 73 PDUFA Date 73 Announces Publication 73 Prognostic Significance 73 Radiofrequency Ablation 73 Gene Variant 73 Novel Treatments 73 Endometrial Cancer 73 HER2 Positive 73 Psoriasis Drug 73 Gene Variants 73 Blood Pressure Drug 73 Kidney Function 73 Sirolimus Eluting Stent 73 Diabetic Patients 73 Advanced Pancreatic Cancer 73 Treatment Naive Patients 73 Submits IND 73 Shows Promise 73 Vaccine Candidate 73 Cardiotoxicity 73 Investigational Oral 73 Patent Issued 73 R lenalidomide 73 Autoimmune Disease 73 Stent Restenosis 73 Announces Presentation 73 Multicenter Trial 73 Intravenous Formulation 73 MEK Inhibitor 73 Slows Progression 73 PRN FDA Approves 73 Intracranial Aneurysms 73 FDA Approves 73 Biomarker Study 73 See CLINICAL PHARMACOLOGY 73 Therapeutic Vaccines 73 Autoimmune Diseases 73 Aliskiren 73 Therapeutic Vaccine 73 Humanized Anti 73 Gastric Cancer 73 Romidepsin 73 Acute Ischemic Stroke 73 Stent Thrombosis 73 Eluting Stent 73 Ranolazine 73 Immunotherapeutic 73 Asthma Treatment 73 Patient Enrolment 73 Cholesterol Drugs 73 Beta Blocker 73 Demonstrates Statistically Significant 73 Multicenter Phase 73 Drug Combo 73 Prostate Cancer Treatment 73 Teva Provides Update 73 Fixed Dose 73 Demonstrates Sustained 73 Abstract Accepted 73 Personalized Immunotherapy 73 Aurora Kinase 73 Chronic Sinusitis 73 Venous Thromboembolism 73 Anticancer Agent 73 Interferon Gamma 73 Pafuramidine 73 Combo Therapy 73 Nuvelo Announces 73 Anti Clotting Drug 73 Smooth Muscle 73 Initiates Phase 2b 73 Capsules CII 73 Phase III Pivotal 73 Lung Cancers 73 Randomized Controlled 72 Carotid Stenting 72 Synta Announces 72 Oral Presentation 72 Regenerative Cells 72 Dose Finding 72 Receptor Antagonist 72 Smallpox Vaccine 72 Gene Linked 72 Increased Mortality 72 Antiviral Therapy 72 Topical Treatment 72 Acute Heart Failure 72 pralatrexate injection folate analogue 72 Molecular Diagnostic Test 72 FDA Clearance 72 Cancer Immunotherapy 72 Novel Therapeutic 72 Inhaled Insulin 72 Test Detects 72 Stem Cell Treatment 72 Multicenter Study 72 Enlarged Prostate 72 Atopic Dermatitis 72 Schizophrenia Treatment 72 Refractory Hodgkin Lymphoma 72 Reveals Positive 72 Hepatic Encephalopathy 72 Demonstrate Significant 72 Phase III Pivotal Trial 72 Drug Resistant 72 Telik Announces 72 Clostridium difficile Infection 72 Inhaled Corticosteroids 72 Mouse Models 72 Announce License Agreement 72 Successfully Treated 72 Receives Fast Track 72 Bare Metal Stents 72 Anticancer Compound 72 Localized Prostate Cancer 72 Pharmacodynamics 72 Secondary Hyperparathyroidism 72 Unresectable 72 Fast Track Status 72 Attenuates 72 Confirms Efficacy 72 Treatment Naive 72 Initiated Phase 72 Showed Significant 72 Breast Cancer Patients 72 Liver Metastases 72 Vascular Disrupting Agent 72 Systemic Sclerosis 72 Antitumor 72 Efficacious 72 Artery Disease 72 Bosutinib 72 Left Ventricular 72 Solid Tumors 72 Presents Positive Preclinical 72 Soft Tissue Sarcoma 72 Anticancer Drugs 72 Malaria Vaccine 72 Tumor Targeting 72 Fondaparinux 72 IIa Clinical Trial 72 Phospholipase A2 72 FOLOTYN ® 72 Diabetic Foot Ulcer 72 Telaprevir VX 72 Multicenter Randomized 72 Nilotinib 72 Non Invasive Treatment 72 Selective Cardiac Myosin 72 Significant Improvement 72 Therapeutic Targets 72 Cell Lymphoma 72 Inflammatory Diseases 72 FDA Approves Drug 72 Anemia Drug 72 Postmenopausal Osteoporosis 72 ASCO GI 72 Polymerase Inhibitor 72 Diabetic Neuropathy 72 Peginterferon Alfa 2a 72 Ovarian Cancer Patients 72 Immunogenicity 72 Sustained Efficacy 72 Serious Infections 72 Receives SFDA Approval 72 Seasonal Influenza Vaccine 72 Node Positive 72 Long Term Survival 72 Oral Mucositis 72 Therapeutic Efficacy 72 Radical Prostatectomy 72 Neuroprotective Effects 72 Peginterferon 72 Lung Cancer Survival 72 Chronic Heart Failure 72 Laryngeal Cancer 71 Controlled Clinical Trial 71 Antiangiogenic 71 Peginterferon Alfa 2b 71 Inhibits 71 Cardiovascular Events 71 Flamel Technologies Announces 71 Treatment Shows Promise 71 Malignant Melanoma 71 AASLD Meeting 71 Epidermal Growth Factor Receptor 71 Sustained Reduction 71 Blood Thinner 71 Sirolimus Eluting 71 Clinical Study Shows 71 Inflammatory Disease 71 Initiates Dosing 71 Universal Flu Vaccine 71 Dose Ranging 71 Osteoarthritis Patients 71 AVI BioPharma Announces 71 Insulin Glargine 71 Pharmacokinetics PK 71 Safety Tolerability 71 Antidepressant Drug 71 Submits Biologics License Application 71 Refractory Angina 71 Cancer Therapies 71 Minimally Invasive Treatment 71 Breast Tumors 71 Tumor Cells 71 Kinase Inhibitors 71 dependent kinase inhibitor 71 Less Invasive 71 BioElectronics Announces 71 Non Inferiority 71 Receives Positive Opinion 71 Contrast Agents 71 Study Indicates 71 Renal Cell Cancer 71 Partial Onset Seizures 71 Aflibercept 71 Medoxomil 71 Hepatitis B Vaccine 71 Cypher Sirolimus 71 Erectile Dysfunction Drug 71 Bazedoxifene 71 Preclinical Evaluation 71 Study Shows Benefits 71 Immunosuppression 71 Positive Opinion 71 Parathyroid Hormone 71 Licenses Novel 71 Poniard Pharmaceuticals Announces 71 Liver Tumors 71 Endovascular Treatment 71 VIVUS Announces 71 Enrolls First 71 Angiogenic 71 Double Blind Randomized 71 Sipuleucel T 71 Urinary Incontinence 71 Chemotherapeutic Agents 71 Reduces Risk 71 Mg Usa 71 Pemphigus Vulgaris 71 Oncology Compounds 71 Shown Effective 71 Anti Angiogenic 71 Taro Receives 71 Long Term Outcomes 71 Cancer Cells 71 Gene Variation 71 Supplemental Biologics License Application 71 Genes Predict 71 Critically Ill Patients 71 Metabolic Disorder 71 Randomized Phase III 71 Estrogen Therapy 71 Thyroid Hormone 71 Romiplostim 71 Advanced Ovarian Cancer 71 Receive Milestone Payment 71 Anti Inflammatory Drug 71 Prospective Multicenter 71 Viral Infections 71 Drug Coated Stent 71 Efficacy Results 71 Fracture Risk 71 Diagnostic Criteria 71 Xcytrin R 71 Subtypes 71 Carboplatin Paclitaxel 71 Gene Therapy Trial 71 Glatiramer Acetate 71 Anthracycline 71 Allergic Rhinitis 71 Bipolar Depression 71 Risk Stratification 71 Novel Method 71 Antigen Specific 71 Hyperlipidemia 71 Kidney Transplant Recipients 71 Blocked Arteries 71 Submits Response 71 Cardiovascular Outcomes 71 Protein Synthesis 71 Oral Anticoagulant 71 Diabetic Kidney Disease 71 Extended Release 71 Drug Eluting Stent 71 Percutaneous Tibial Nerve Stimulation 71 Drug Prevents 71 Renal Impairment 71 Dose Escalation Study 71 Guidelines Recommend 71 Newly Diagnosed Patients 71 Golimumab 71 Skin Lesions 71 Antiplatelet 71 Bladder Cancer 71 Drug Eluting Stents 71 Insulin Resistance 71 Menopausal Women 71 Chemotherapy Regimen 71 Prognostic Value 71 Progenitor Cells 71 Clinical Trial 71 Catheter Ablation 71 Generic Versions 71 Patient Treated 71 Acute Myocardial Infarction 71 Acute Attacks 71 Patient Outcomes 70 ORLive Presents 70 Cethromycin 70 Announces Positive 70 Potentially Fatal 70 Diabetic Neuropathic Pain 70 Recurrent Breast Cancer 70 Denufosol 70 SPRYCEL ® 70 Antiviral Drugs 70 PROSTASCINT R 70 Nucleoside 70 Drug Coated Stents 70 Results Confirm 70 Shows Statistically Significant 70 Levels Linked 70 Oral Insulin 70 Experimental Vaccine 70 Poster Presentation 70 Anticoagulant 70 Hepatitis C Treatment 70 Pegylated 70 Dasatinib 70 Fewer Side Effects 70 Epratuzumab 70 Pharmaceuticals Initiates 70 Lanthanum Carbonate 70 TO AVOID PREGNANCY WHILE 70 Genes Linked 70 Companion Diagnostic 70 Adenoma 70 Tiotropium 70 Protease Inhibitors 70 Randomised Trial 70 Effective Than 70 Anti CD# Antibody 70 Acute Migraine 70 Premature Infants 70 Projected Release Date 70 Significant Improvements 70 Blood Pressure Lowering 70 Telbivudine 70 Files Patent Application 70 Increases Risk 70 Aggressive Prostate Cancer 70 dual endothelin receptor antagonist 70 Novel Therapies 70 Antiplatelet Therapy 70 Total Knee Arthroplasty 70 Antibody Drug Conjugate 70 Treating Heart Failure 70 Immune Cell 70 Naive Patients 70 LENALIDOMIDE 70 Liver Toxicity 70 Breast Cancer Treatment 70 Increased Risk 70 Reports Positive 70 FDA Panel Recommends 70 Immune Cells 70 Left Ventricular Hypertrophy 70 Cocaine Addiction 70 Diagnostic Tests 70 Cancer Vaccines 70 Dual Antiplatelet Therapy 70 Transdermal Delivery 70 Symptom Relief 70 Vaccine Protects Against 70 IL# PE#QQR 70 Premenopausal Women 70 Weight Loss Drug 70 Avian Flu Vaccine 70 Randomized Placebo Controlled Trial 70 J Clin 70 Milestone Payments 70 Hepatitis C Virus 70 Ozarelix 70 Observational Study 70 Statin Drugs 70 Hematological 70 Cognitive Impairment 70 ST Elevation Myocardial 70 Stem Cell Transplants 70 Renal Tumors 70 Hepatitis C Patients 70 Zoledronic Acid 70 Colorectal Adenomas 70 Receives Complete Response 70 Paclitaxel Carboplatin 70 Genes Involved 70 Tesetaxel 70 Atypical Hemolytic Uremic Syndrome 70 Contrast Agent 70 Study Shows Promise 70 Induces 70 Protein Linked 70 Advanced Solid Tumors 70 Phase IIa Trial 70 Ischemic Stroke 70 Randomized Controlled Trial 70 Successful Completion 70 Generalized Anxiety Disorder 70 Orthostatic Hypotension 70 J Am Coll 70 Tuberculosis Vaccine 70 Bortezomib 70 Positive Results 70 Technological Advances 70 Outpatient Setting 70 Treatment Regimens 70 Pre Cancerous 70 Antipsychotic Drug 70 Improve Outcomes 70 FDA APPROVES 70 Cetrorelix 70 Metastatic Pancreatic Cancer 70 Early Diagnosis 70 Factor Receptor 70 Seasonal Allergic Rhinitis 70 Drug Eluting Coronary Stent 70 Prognostic Factors 70 Obese Patients 70 Interferon Alpha 70 Alvine Pharmaceuticals 70 REG1 Anticoagulation System 70 Develops Novel 70 Uterine Fibroid Embolization 70 Multiple Ascending Dose 70 Cannabinoid 70 Newly Identified 70 Treatment Naïve Patients 70 Monoclonal Antibodies 70 Therapy Shows Promise 70 Ambrisentan 70 BioSante Pharmaceuticals Announces 70 Lipid Levels 70 Study Validates 70 Prostate Tumors 70 Bone Mineral Density 70 Demonstrates Ability 70 Anti Inflammatory 70 Multicenter 70 non nucleoside inhibitor 70 Epilepsy Drugs 70 Help Predict 70 Mimetics 70 Study Proves 69 BioSante Pharmaceuticals Reports 69 Potent Anti 69 Enoxaparin 69 Aztreonam Lysine 69 Oral Cladribine 69 Protein Involved 69 Inhaled Liposomal Ciprofloxacin 69 Therapeutic Competitors companiesandmarkets.com adEgemonye 69 Virus Infection 69 Complete Remission 69 Molecular Mechanism 69 Announce Collaboration Agreement 69 Receives Positive 69 Receptor Antagonists 69 Carotid Endarterectomy 69 Hepatitis C Genotype 69 Embolic Protection 69 Cardiac Function 69 Circulating Tumor Cells 69 Invasive Breast Cancer 69 Syncria R 69 Oral Interferon 69 Implantable Device 69 Taxane 69 Antifungal 69 Dupuytren Contracture 69 Inhalation Solution 69 Crit Rev 69 VIVITROL ® 69 Announcement acc 69 Milestone Payment From 69 oral prodrug 69 Arterial Disease 69 Antipsychotic 69 Hormone Therapy 69 Significant Reduction 69 AnaSpec Introduces 69 Methylnaltrexone 69 Fabry Disease 69 Rigel R# 69 Heartburn Drugs 69 Orthop Surg 69 MBRX 69 Gentium Announces 69 PEGylated Fab fragment 69 Epoetin Alfa 69 BiTE Antibody 69 Tablet Formulation 69 Carcinomas 69 Commercialize Novel 69 Biogen Genentech 69 DIRECT Trial 69 Pirfenidone 69 Menopausal Symptoms 69 Endothelial Cells 69 Panic Disorder 69 Viral Suppression 69 Balloon Angioplasty 69 Chemoradiation 69 lexidronam injection 69 Invasive Fungal Infections 69 Million Milestone Payment 69 ORAL Sync 69 Begins Shipment 69 Myelofibrosis 69 Male Contraceptive 69 Novel Vaccine 69 Sign Licensing Agreement 69 GATTEX TM 69 Anti Angiogenesis 69 fosbretabulin 69 Vivo Efficacy 69 Randomized Comparison 69 investigational humanized monoclonal antibody 69 Skeletal Muscle 69 Androgen Receptor 69 J Allergy Clin 69 Pivotal Phase II 69 DOR BioPharma Announces 69 Psoriasis Patients 69 Aptamer 69 Immune Mediated 69 Cancer Stem Cells 69 Surgical Treatment 69 Metabolic Disease 69 Cytotoxicity 69 pan HDAC inhibitor 69 Atypical Antipsychotic 69 Malignancies 69 Trodusquemine MSI 69 Renal Function 69 Myocardial Ischemia 69 Brain Atrophy 69 Gastrointestinal Stromal Tumors 69 Stomach Cancer 69 Sustained Release 69 Results Indicate 69 Kidney Transplants 69 Resubmission 69 Cognitive Decline 69 Tigecycline 69 Cell Transplants 69 Breast Density 69 Targeted Therapy 69 Autoimmune Disorders 69 Severe Asthma 69 Archexin 69 Bucindolol 69 Vildagliptin 69 Protein Expression 69 Chronic Myelogenous Leukemia 69 Activator CK # 69 Oritavancin 69 ERBITUX cetuximab 69 Genetic Tests 69 Stent Placement 69 LibiGel ® 69 Migraine Treatment 69 Inhaled Nitric Oxide 69 Differential Diagnosis 69 Optimer Pharma 69 Antiepileptic Drugs 69 XPEL Announces 69 Thrombotic 69 Osteoarthritis Pain 69 Data Indicate 69 Statistical Significance 69 investigational oral inhibitor 69 Cervical Dysplasia 69 Newly Diagnosed Breast Cancer 69 Non Responders 69 Genetic Mutation 69 Study Shows Significant 69 Preterm Infants 69 Androgen Deprivation Therapy 69 Peripheral Artery Disease 69 Antisense Drug 69 Signaling Pathways 69 Chemotherapy Improves 69 Gene Silencing 69 Testosterone Gel 69 Disease IBD 69 IN PATIENTS WITH 69 Receives CE Marking 69 Oral Spray 69 Diabetic Macular Edema 69 Proc Am Soc 69 Cell Transplant 69 Blood Clotting 69 Cholesterol Lowering 69 Study Confirms 69 Novel Compounds 69 Hyperthermia Therapy 69 Hedgehog Pathway 69 Effective Treatments 69 evaluating tivozanib 69 Gastrointestinal Disorders 69 ThermoDox R 69 Acute Coronary Syndromes 69 Viral Load 69 PROVENGE ® 69 Clinical Validation 69 Iron Overload 69 Aethlon Medical Releases 69 Follicular Lymphoma 69 Cognitive Function 69 Diastolic Heart Failure 69 Tumor Response 69 Pulmonary Artery 69 Reduces Mortality 69 Submits Supplemental 69 Therapy Reduces 69 Malignant Glioma 69 Enzyme Replacement Therapy 69 VIVUS Qnexa 69 Prostate Biopsy 69 Antibiotic Treatment 69 Melphalan 69 Myelodysplastic Syndrome MDS 69 mGluR5 negative 69 Microplasmin 69 Chronic Bronchitis 69 Bavituximab 69 Blood Cancers 69 Provides Update Regarding 69 Sleep Disturbances 69 Gene Mutations 69 ISTODAX ® 69 Pharmacodynamic 69 Poster Discussion 69 Key Milestones 68 Reduced Risk 68 Chronic Constipation 68 BIOLASE Announces 68 Predict Response 68 Migraine Pain 68 Hepatitis C Infection 68 Commonly Used 68 Pharmacokinetic 68 Genetic Variations 68 Virus Linked

Back to home page